Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
FDA nominee addresses recent staff cuts, divestment and recusal commitments, and post‑market surveillance
Summary
Dr. Marty Makary told senators he will assess recent personnel cuts at the FDA if confirmed, has voluntarily divested investments flagged in an ethics review, and supports stronger post‑market surveillance and review of user‑fee uses.
Dr. Marty Makary told the Senate HELP Committee that he would undertake an assessment of personnel, staffing and funding at the Food and Drug Administration if confirmed, responding to multiple senators’ concerns about recent layoffs and the agency’s ability to carry out inspections and reviews.
"If confirmed, you have my commitment that I will do an assessment within the agency of personnel," Dr. Makary said, adding that he would seek to ensure scientists and inspectors "have all the resources they need to do their job."
Several senators told the nominee that roughly 10 percent of…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
